We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+23.65%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.28B
AUM Growth
+$464M
Cap. Flow
-$292M
Cap. Flow %
-5.53%
Top 10 Hldgs %
49.47%
Holding
185
New
37
Increased
47
Reduced
83
Closed
9

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$120M
2
FOLD
Amicus Therapeutics
FOLD
+$105M
3
NUVL
Nuvalent
NUVL
+$102M
4
KRYS icon
Krystal Biotech
KRYS
+$86.1M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$75.6M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$149M
2
INCY icon
Incyte
INCY
+$139M
3
AKRO
Akero Therapeutics
AKRO
+$113M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$109M
5
ARGX icon
argenx
ARGX
+$72.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Technology 0.1%
3 Consumer Discretionary 0.05%
4 Financials 0.03%
5 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDLN
76
Medline Inc
MDLN
$32.8B
$4.94M 0.09%
+117,720
New +$4.97M
ADPT icon
77
Adaptive Biotechnologies
ADPT
$3.56B
$4.84M 0.09%
298,090
+129,614
+77% +$2.12M
ICLR icon
78
Icon
ICLR
$12.8B
$4.48M 0.08%
24,560
+313
+1% +$55.7K
BNTX icon
79
BioNTech
BNTX
$22.6B
$4.17M 0.08%
43,755
+9,800
+29% +$987K
BMRN icon
80
BioMarin Pharmaceuticals
BMRN
$11.5B
$3.86M 0.07%
65,008
-36,025
-36% -$1.96M
BMY icon
81
Bristol-Myers Squibb
BMY
$127B
$3.62M 0.07%
67,082
+19,469
+41% +$937K
BTSG icon
82
BrightSpring Health Services
BTSG
$14.3B
$3.45M 0.07%
92,095
-98,429
-52% -$3.3M
NEO icon
83
NeoGenomics
NEO
$1.81B
$3.27M 0.06%
278,286
-91,912
-25% -$992K
AVTR icon
84
Avantor
AVTR
$7.81B
$3.17M 0.06%
276,266
+172,904
+167% +$2.13M
PHR icon
85
Phreesia
PHR
$632M
$3.1M 0.06%
183,213
-129,844
-41% -$2.68M
BEAM icon
86
Beam Therapeutics
BEAM
$2.58B
$3.09M 0.06%
111,510
-2,777,778
-96% -$70.9M
KMTS
87
Kestra Medical Technologies
KMTS
$1.23B
$3.07M 0.06%
115,755
-12,956
-10% -$334K
ILMN icon
88
Illumina
ILMN
$29.4B
$3.01M 0.06%
22,940
-857
-4% -$101K
OMDA
89
Omada Health Inc
OMDA
$1.22B
$2.81M 0.05%
177,897
-73,894
-29% -$1.5M
AZN icon
90
AstraZeneca
AZN
$263B
$2.8M 0.05%
15,216
-2,606
-15% -$457K
INSM icon
91
Insmed
INSM
$23.2B
$2.42M 0.05%
13,915
-6,336
-31% -$1.16M
VKTX icon
92
Viking Therapeutics
VKTX
$4.04B
$2.42M 0.05%
68,665
-7,417
-10% -$263K
ROIV icon
93
Roivant Sciences
ROIV
$25.2B
$2.34M 0.04%
+108,039
New +$2.13M
BBNX
94
Beta Bionics
BBNX
$706M
$2.2M 0.04%
72,285
+8,002
+12% +$214K
SPY icon
95
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$2.11M 0.04%
3,100
– –
EHC icon
96
Encompass Health
EHC
$11.2B
$2.03M 0.04%
19,089
-103,869
-84% -$12M
UTHR icon
97
United Therapeutics
UTHR
$26.3B
$1.9M 0.04%
3,895
+1,255
+48% +$584K
BBIO icon
98
BridgeBio Pharma
BBIO
$16.5B
$1.84M 0.03%
24,111
+3,755
+18% +$246K
BKD icon
99
Brookdale Senior Living
BKD
$3.62B
$1.81M 0.03%
167,444
+62,779
+60% +$617K
SIBN icon
100
SI-BONE Inc
SIBN
$737M
$1.78M 0.03%
90,331
-208,526
-70% -$3.62M
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2025 Portfolio in Review

As of Q4 2025, Bellevue Group held 185 positions worth $5.28B, up 9.6% from $4.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $292M in Q4 2025, closing 9 positions and reducing 83 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Viridian Therapeutics worth $136M.

  • Bellevue Group's largest Q4 2025 buy was Viridian Therapeutics: 4,358,527 shares worth $136M.
  • Bellevue Group added most to Krystal Biotech in Q4 2025, an estimated $86.1M increase.
  • Bellevue Group's biggest Q4 2025 reduction was Incyte, cutting an estimated $139M.
  • Bellevue Group fully exited Agios Pharmaceuticals in Q4 2025, selling an estimated $149M.
  • Bellevue Group's ten largest holdings make up 49% of its $5.28B portfolio in Q4 2025.
  • Bellevue Group opened 37 new positions and closed 9 in Q4 2025.
  • Bellevue Group's portfolio value rose 9.6% quarter-over-quarter to $5.28B.

Based on Bellevue Group's 13F filing for Q4 2025, filed 17 Feb 2026.